ID   SEM
AC   CVCL_0095
DR   EFO; EFO_0002326
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioGRID_ORCS_Cell_line; 1548
DR   BioSample; SAMN03473532
DR   BioSample; SAMN10988273
DR   cancercelllines; CVCL_0095
DR   Cell_Model_Passport; SIDM01424
DR   ChEMBL-Cells; CHEMBL4295399
DR   ChEMBL-Targets; CHEMBL4296493
DR   Cosmic; 1130254
DR   Cosmic; 2491076
DR   Cosmic; 2542839
DR   DepMap; ACH-000782
DR   DSMZ; ACC-546
DR   DSMZCellDive; ACC-546
DR   GEO; GSM887563
DR   GEO; GSM888646
DR   GEO; GSM5137743
DR   GEO; GSM5137744
DR   IARC_TP53; 28231
DR   IGRhCellID; SEM
DR   LiGeA; CCLE_736
DR   PharmacoDB; SEM_1363_2019
DR   PRIDE; PXD023662
DR   Progenetix; CVCL_0095
DR   PubChem_Cell_line; CVCL_0095
DR   Wikidata; Q54952795
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=7794749;
RX   PubMed=8199015;
RX   PubMed=9067587;
RX   PubMed=9881706;
RX   PubMed=14671638;
RX   PubMed=20215515;
RX   PubMed=21552520;
RX   PubMed=22460905;
RX   PubMed=25984343;
RX   PubMed=26589293;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
RX   PubMed=31978347;
RX   PubMed=35354797;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: LL-100 blood cancer cell line panel.
CC   Population: Caucasian.
CC   Doubling time: ~48 hours (PubMed=8199015); 24 hours (PubMed=25984343); ~30 hours (DSMZ=ACC-546).
CC   HLA typing: A*01:01,32:01; B*08:01,15:01; C*03:03,07:01 (PubMed=26589293).
CC   HLA typing: A*01:01:01,32:01:01; B*08:01:01,15:01:01; C*03:03:01,07:01:01; DPA1*01:03:01,01:03:01; DPB1*04:02:01,02:01:02; DQA1*01:03:01,01:03:01; DQB1*03:01:01,06:03:01; DRA*01:01:01,01:02:02; DRB1*11:01:01,13:01:01 (DSMZCellDive=ACC-546).
CC   Microsatellite instability: Instable (MSI) (PubMed=31068700).
CC   Sequence variation: Gene fusion; HGNC; 7135; AFF1 + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFF1, MLL-AFF1, ALL-1/AF4 (PubMed=14671638; PubMed=35354797).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Heterozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative phosphoproteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.88%; Native American=0.05%; East Asian, North=2.53%; East Asian, South=0%; South Asian=0.07%; European, North=64.12%; European, South=32.35% (PubMed=30894373).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): DSMZ
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 14
ST   D16S539: 8,10
ST   D18S51: 16,17
ST   D19S433: 13,14
ST   D21S11: 29,30,31
ST   D2S1338: 17,24
ST   D3S1358: 14,17
ST   D5S818: 12
ST   D7S820: 10,12
ST   D8S1179: 11,14
ST   FGA: 21,25
ST   Penta D: 11,14
ST   Penta E: 10,11
ST   TH01: 6,10
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C9140; Childhood B acute lymphoblastic leukemia
DI   NCIt; C80342; B acute lymphoblastic leukemia with t(v;11q23.3) MLL rearranged
DI   ORDO; Orphanet_585918; B-lymphoblastic leukemia/lymphoma with t(v;11q23.3)
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   5Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 30
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=7794749; DOI=10.1111/j.1365-2141.1995.tb05151.x;
RA   Marschalek R., Greil J., Lochner K., Nilson I., Siegler G.,
RA   Zweckbronner I., Beck J.D., Fey G.H.;
RT   "Molecular analysis of the chromosomal breakpoint and fusion
RT   transcripts in the acute lymphoblastic SEM cell line with chromosomal
RT   translocation t(4;11).";
RL   Br. J. Haematol. 90:308-320(1995).
//
RX   PubMed=8199015; DOI=10.1111/j.1365-2141.1994.tb04726.x;
RA   Greil J., Gramatzki M., Burger R., Marschalek R., Peltner M.,
RA   Trautmann U., Hansen-Hagge T.E., Bartram C.R., Fey G.H., Stehr K.,
RA   Beck J.;
RT   "The acute lymphoblastic leukaemia cell line SEM with t(4;11)
RT   chromosomal rearrangement is biphenotypic and responsive to
RT   interleukin-7.";
RL   Br. J. Haematol. 86:275-283(1994).
//
RX   PubMed=9067587; DOI=10.1038/sj.leu.2400571;
RA   Uphoff C.C., MacLeod R.A.F., Denkmann S.A., Golub T.R., Borkhardt A.,
RA   Janssen J.W.G., Drexler H.G.;
RT   "Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in
RT   human early B-lineage leukemia cell lines.";
RL   Leukemia 11:441-447(1997).
//
RX   PubMed=9881706; DOI=10.1038/sj.onc.1202229;
RA   Reichel M., Gillert E., Nilson I., Siegler G., Greil J., Fey G.H.,
RA   Marschalek R.;
RT   "Fine structure of translocation breakpoints in leukemic blasts with
RT   chromosomal translocation t(4;11): the DNA damage-repair model of
RT   translocation.";
RL   Oncogene 17:3035-3044(1998).
//
RX   PubMed=14671638; DOI=10.1038/sj.leu.2403236;
RA   Drexler H.G., Quentmeier H., MacLeod R.A.F.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   MLL gene alterations.";
RL   Leukemia 18:227-232(2004).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21552520; DOI=10.1371/journal.pone.0019169;
RA   Gu T.-L., Nardone J., Wang Y., Loriaux M., Villen J., Beausoleil S.A.,
RA   Tucker M., Kornhauser J.M., Ren J.-M., MacNeill J., Gygi S.P.,
RA   Druker B.J., Heinrich M.C., Rush J., Polakiewicz R.D.;
RT   "Survey of activated FLT3 signaling in leukemia.";
RL   PLoS ONE 6:E19169-E19169(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35354797; DOI=10.1038/s41467-022-29224-5;
RA   Leo I.R., Aswad L., Stahl M., Kunold E., Post F., Erkers T.,
RA   Struyf N., Mermelekas G., Joshi R.N., Gracia-Villacampa E.,
RA   Ostling P., Kallioniemi O.-P., Pokrovskaja Tamm K., Siavelis I.,
RA   Lehtio J., Vesterlund M., Jafari R.;
RT   "Integrative multi-omics and drug response profiling of childhood
RT   acute lymphoblastic leukemia cell lines.";
RL   Nat. Commun. 13:1691.1-1691.19(2022).
//